Table 3 Symptoms, signs, and cardiac investigation findings of patients with thyrotoxicosis at the endocrine clinic, ACSH from December, 2017 to June, 2018, N = 200
From: Thyrotoxicosis and dilated cardiomyopathy in developing countries
Clinical features | Frequency | Percentage (95 % CI) | |
|---|---|---|---|
Symptoms | |||
Palpitation | 171 | 85.5 (79.8–90.1) | |
Fatigue | 138 | 69.0 (62.1–75.3) | |
Heat intolerance | 118 | 59.0 (51.8–65.9) | |
Irritability | 110 | 55.0 (47.8–62.0) | |
Hyperactivity | 104 | 52.0 (44.8–59.1) | |
Sweating | 89 | 44.5 (37.5–51.7) | |
Weight loss | 70 | 35.0 (28.4–42.0) | |
Increased appetite | 66 | 33.0 (26.5–40.0) | |
Difficulty of swallowing | 10 | 5.0 (2.4-9.0) | |
Dyspnea | 10 | 5.0 (2.4-9.0) | |
Abortion | 6 | 3.0 (1.1–6.4) | |
Dysmenorrhea | 4 | 2.0 (0.5-5.0) | |
Signs | |||
Anterior neck swelling | 186 | 93.0 (88.5–96.1) | |
Tachycardia | 86 | 43.0 (36.0-50.2) | |
Exophthalmos | 35 | 17.5 (12.5–23.5) | |
Tremor | 35 | 17.5 (12.5–23.5) | |
Lid lag | 2 | 1.0 (0.1–3.6) | |
Lid retraction | 1 | 0.5 (0.0-2.8) | |
Echo (n = 89) | |||
Dilated cardiomyopathy | 35 | 39.3 (29.1–50.3) | |
Normal | 20 | 22.5 (14.3–32.6) | |
Pulmonary hypertension | 17 | 19.1 (11.5–28.8) | |
Degenerative valvular heart disease | 9 | 10.1 (4.7–18.3) | |
Rheumatic valvular heart disease | 6 | 6.7 (2.5–14.1) | |
Hypertensive heart disease | 2 | 2.2 (0.0-7.9) | |
ECG (n = 149) | |||
Sinus tachycardia | 71 | 47.7 (39.4–56.0) | |
Atrial fibrillation | 43 | 28.9 (21.7–36.8) | |
Normal | 35 | 23.5 (16.9–31.1) | |
Sinus bradycardia | 1 | 0.7 (0.0-3.7) | |